1. Home
  2. PMCB vs ALZN Comparison

PMCB vs ALZN Comparison

Compare PMCB & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.49

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Logo Alzamend Neuro Inc.

ALZN

Alzamend Neuro Inc.

HOLD

Current Price

$1.66

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMCB
ALZN
Founded
1996
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
7.5M
IPO Year
2001
2021

Fundamental Metrics

Financial Performance
Metric
PMCB
ALZN
Price
$0.49
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
84.1K
83.8K
Earning Date
03-17-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
76.77
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.84
52 Week High
$1.51
$2.68

Technical Indicators

Market Signals
Indicator
PMCB
ALZN
Relative Strength Index (RSI) 31.46 65.28
Support Level N/A $1.41
Resistance Level $0.57 $2.25
Average True Range (ATR) 0.03 0.11
MACD -0.00 0.00
Stochastic Oscillator 20.99 90.32

Price Performance

Historical Comparison
PMCB
ALZN

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

About ALZN Alzamend Neuro Inc.

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Share on Social Networks: